Candia, Jimboy M.
HRN: 20-48-83 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/06/2024
OXACILLIN 500MG (VIAL)
08/06/2024
08/13/2024
400 MG
IV
Q6H
Carbunculosis
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes